A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this study is to evaluate the effect of age on PK, safety and tolerability of IV rivipansel.

Key facts

Study ID

NCT02998099

Run by

GlycoMimetics Incorporated

People needed

16

Starts

2017-01-01

Expected to finish

2017-03-01

Last updated by the study team

2020-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy female subjects of non-childbearing potential or healthy male subjects who are between the ages of 18-45 years or 65 years of age or older.
• Body mass index (BMI) of 17.5 to 40 kg/m2

You may not qualify if…

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
• Pregnant females; breastfeeding female subjects; male subjects with partners currently pregnant
• Treatment with another investigational drug within 30 days or 5 half-lives preceding the dose of study medication
• Blood donation within 60 days prior to dosing.

Where it is running

• Orlando Clinical Research Center — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.